ClinicalTrials.gg
CompletedNCT07295496Updated Nov 16, 2026

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011

A Phase 1 interventional study of IBI3011 and IBI3011 Placebo in Acute Gout Flare, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 49 studies in Gout with a site in China — 11 open to participants now, 15 under way, 2 of them phase 3. Gout · China.

Enrollment
28th of 44
64 · median 93
Started
2025
with 3 others
Phase 1
16 of 49
4 open now
Registered
39th of 49
by date
Lead sponsor
2 of 49
Innovent Biologics (Suzhou) Co. Ltd.

Among the 49 studies in Gout with a site in China, this one is the 28th largest by enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2025, is one of 16 in phase 1, and was the 39th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

11 of the 49 studies in Gout with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Gout with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanised monoclonal antibody injection in healthy Chinese subjects (Part A) and subjects with acute gout flare (Part B)

03

Conditions studied

  • Acute Gout Flare

Browse trials for

Keywords

  • acute gout flare
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects are eligible for the study if they meet all of the following Inclusion Criteria:

  1. Age ≥18 years of age, male or female;
  2. (BMI) 18-26 kg/m2 (inclusive) for Part A healthy subjects and BMI 18-40 kg/m2 (inclusive) for Part B acute gout flare subjects; Part B acute gout flare subjects also needed to meet the following criteria
  3. Meet ACR 2015 preliminary criteria for the classification of acute arthritis of primary gout;
  4. Other inclusion criteria set by protocol

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria are not eligible to attend this clinical study:

  1. Difficulties in venous blood collection or a history of dizziness when encountering blood or needles;
  2. Have received an experimental agent within 1 month or 5 times half-life (whichever is longer) prior;
  3. Have live or attenuated vaccination in the 3 months before randomization or plan to receive that during this trial;
  4. Blood donation or blood loss of more than 400 mL within 8 weeks before the screening;
  5. Have a history of severe infection, severe trauma, or major surgical procedures within 6 months before the screening;
  6. History of ;
  7. Female during pregnancy or lactation;
  8. Have a history of drug abuse, drug dependence, or a positive result in a drug screen within 12 months before the screening;
  9. Has a history of neuropsychiatry or any other disease/ailment that is unsuitable for this clinical trial at the discretion of the Investigator;

    Part B acute gout flare subjects also needed to exclude the following criteria:

  10. Secondary gout (e.g., gout induced by chemotherapy, transplant-related gout);
  11. Infection/septic arthritis, or other acute inflammatory arthritis;
  12. Other exclusion criteria set by protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    IBI3011 placebo group

    Drug: IBI3011 Placebo

  • Experimental
    IBI3011

    IBI3011 group

    Drug: IBI3011

Interventions

  • DrugIBI3011

    * Anti-IL-RAP humanised monoclonal antibody injection * 300 mg (2.0 mL)/vial * Administered in accordance with the study protocol * Single administration only

  • DrugIBI3011 Placebo

    * Anti-IL-RAP humanised monoclonal antibody placebo injection * 300 mg (2.0 mL)/vial * Administered in accordance with the study protocol * Single administration only

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To investigate the safety characteristics.

    Time frame: 12 week

Secondary outcomes

  1. Immunogenic outcome

    The incidence of antidrug Antibody (ADA) and/or Neutralising antibodies (NAb)

    Time frame: 12 week

  2. AUC

    Describing the Area Under Curve

    Time frame: 12 Week

  3. Cmax

    Describing the Maximum Serum Concentration of Drug

    Time frame: 12 Week

  4. CL or CL/F

    Describing the Clearance

    Time frame: 12 Week

  5. V or V/F

    Describing the Apparent Volume of Distribution

    Time frame: 12 Week

  6. t1/2

    Describing the Half Life

    Time frame: 12 Week

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Aug 2026, 7 months.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 7 months is above that.

Counting every sponsor, half of 41 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jun 2026 → Aug 2026 and completion Jun 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 19, 2025
StartActual
Dec 8, 2025
Primary completionActual
Aug 6, 2026was Jun 2026
CompletionActual
Sep 28, 2026was Jun 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Primary completion
Jun 7, 2026→Aug 6, 2026 (actual)
Nov 16, 2026
Study completion
Jun 7, 2026→Sep 28, 2026 (actual)
Nov 16, 2026
Eligibility
Maximum age 100 Years→none
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Primary completion Jun 7, 2026→Aug 6, 2026 (now actual)
    Study completion Jun 7, 2026→Sep 28, 2026 (now actual)
    Eligibility Maximum age 100 Years→none
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07295496
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Dec 8, 2025
Primary completion
Aug 6, 2026
Completion
Sep 28, 2026
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion